The quite unexpected positive cardiorenal outcomes that have emerged from the cardiovascular outcomes trials (CVOTs) with both glucagon like peptide-1 receptors agonists (GLP-1RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have produced a shift of diabetes management from the meticulous glycemic control alone to the simultaneous improvement of CV outcomes. Here, SLC5A2 is linked to diabetes mellitus.